Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Lexaria Bioscience put definitive agreements in place for the immediate cash exercise of warrants covering 453,969 shares at a reduced exercise price of $12.92 per share, expected to generate roughly $5.9 million in gross proceeds, with closing on or about September 9, 2026. The exercised warrants originally carried strikes of $17.85 to $45.90, and as consideration Lexaria will issue new unregistered Series A and Series B warrants, each covering up to 453,969 shares with a $12.67 exercise price — stacking up to 907,938 shares of additional potential dilution. H.C.
Key figures
- Offering Price
- 12.92
- Shares Offered
- 453969
- Gross proceeds
- 5900000
- Series a expiry
- 5 years from Resale Registration Statement effective date
- Series b expiry
- 18 months from Resale Registration Statement effective date
- Australian tax rebate
- 2600000
- New warrant exercise price
- 12.67
- Original warrant exercise prices
- [32.78,45.9,20.55,17.85]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.